Dr Reddy's Srikakulam plant gets USFDA VAI close 2026

What Dr Reddy’s told exchanges

Dr Reddy’s Laboratories said it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its formulations manufacturing facility at Srikakulam, Andhra Pradesh. The company disclosed that the EIR was received on 4 March 2026. The USFDA classified the inspection outcome as Voluntary Action Indicated (VAI). Dr Reddy’s also stated that the regulator has confirmed the inspection is officially closed under 21 CFR 20.64(d)(3). The update matters because USFDA inspection outcomes are closely watched by investors and customers, especially when they involve pre-approval work that can influence product filings and commercial supply.

What the USFDA inspection covered at Srikakulam

According to the company, the inspection covered both a Good Manufacturing Practice (GMP) review and a Pre-Approval Inspection (PAI). The inspection was conducted at the company’s FTO-SEZ PU01 facility. A PAI is typically linked to product approval processes, while the GMP component checks compliance with manufacturing and quality systems. Dr Reddy’s indicated that the USFDA has now closed this inspection after issuing the VAI classification.

Earlier disclosure about the Srikakulam site inspection

Dr Reddy’s said it had earlier informed about the USFDA inspection on 12 December 2025. The latest disclosure clarifies the regulatory endpoint for that inspection cycle, since the EIR has now been issued and the inspection has been marked closed under the cited regulation. The company’s filing does not describe any enforcement action connected to the Srikakulam inspection outcome.

Another Srikakulam inspection referenced in earlier filings

Separately, the material also references an exchange filing dated 24 May 2025 relating to an inspection conducted between 19 May and 24 May 2025. In that instance, the inspection was described as a Pre-Approval Inspection (PAI) at the Srikakulam facility (also referenced as FTO 11). The note says the USFDA issued a Form 483 with two observations at the conclusion of that inspection, and Dr Reddy’s stated it would address them within the stipulated timeline. The same set of text also mentions an EIR date of 20 October 2025 for that inspection and states it was officially closed with a VAI classification.

What “VAI” and “inspection closed” imply

A VAI classification indicates the inspection identified certain issues or observations, but the USFDA does not plan immediate enforcement action based on those findings. In the text provided, this interpretation is explicitly stated for another Dr Reddy’s facility, where it is noted that the FDA expects the company to voluntarily address and rectify concerns raised. The “closed” status, as referenced multiple times alongside 21 CFR 20.64(d)(3), indicates the inspection process has been concluded at that stage. While a closed VAI outcome is generally viewed as less disruptive than outcomes requiring official action, it still places responsibility on the company to complete corrective actions where applicable.

Hyderabad API facility (CTO-2) also received a VAI EIR

Dr Reddy’s also disclosed an EIR from the USFDA for its active pharmaceutical ingredient (API) manufacturing facility (CTO-2) in Bollaram, Hyderabad. This update was reported as having been announced on Tuesday, February 25 (year referenced as 2025 in the provided text). The inspection had been previously disclosed on November 19, 2024, and was classified as VAI. The filing said the USFDA identified certain issues and advised the company to address and resolve these concerns. It also noted that the FDA marked the inspection as “closed”, indicating that no further regulatory steps were required at that stage.

Stock moves and valuation data mentioned alongside the updates

The Srikakulam EIR update was accompanied by the company’s quarterly performance and an immediate stock reaction in the provided material. Dr Reddy’s reported a 14.4% decline in consolidated net profit to Rs 1,209.8 crore, despite a 4.4% jump in revenue to Rs 8,716.8 crore in Q3 FY26 over Q3 FY25. The stock was noted as shedding 0.91% to Rs 1,301.10 on the BSE.

For another period, the company’s consolidated net profit rose 1.8% to Rs 1,418.10 crore on an 11.4% increase in revenue from operations to Rs 8,545.20 crore in Q1 FY26 over Q1 FY25. In that reference, the scrip rose 0.61% to Rs 1,219 on the BSE.

The Hyderabad API facility update also included market and valuation datapoints: on February 27, 2025, the share price traded 0.23% higher at Rs 1,129.15 at 9:24 AM (IST). The same text lists a 52-week high of Rs 1,420.20 and a 52-week low of Rs 1,120.01. It also states that at the current price the shares were trading at a P/E of 18.16x based on trailing 12-month EPS of Rs 62.12, and a P/B of 3.50, according to exchange data.

Key facts table from the disclosures

Why repeated VAI closures matter for operations

Across the snippets, Dr Reddy’s has reported multiple inspections that ended with VAI classifications and closed status, including at a Hyderabad API facility (CTO-2) and a formulations facility at Srikakulam. The closures reduce near-term uncertainty around regulatory follow-ups for the specific inspection cycles referenced, particularly where the inspection includes a pre-approval component. At the same time, the VAI status signals that observations were noted and are expected to be addressed through corrective actions.

The disclosures also show how USFDA outcomes can coincide with stock price movement and renewed focus on financial performance. In the Q3 FY26 reference, revenue growth was reported alongside a decline in consolidated net profit, and the stock was lower on the day. In the Q1 FY26 reference, the company reported higher profit and revenue and the stock was modestly higher.

Conclusion

Dr Reddy’s Laboratories said the USFDA has issued an EIR for its Srikakulam formulations facility and classified the inspection as VAI, while confirming the inspection is closed under 21 CFR 20.64(d)(3). The company had earlier disclosed the inspection in December 2025 and has now shared the formal closure outcome. Separate disclosures in the provided material also point to a similar VAI and closed status for the Bollaram (Hyderabad) API facility (CTO-2), and earlier inspection cycles that included Form 483 observations. The next developments to watch, based on what is stated, are the company’s execution of any corrective actions referenced and further regulatory updates tied to future inspections or product approvals.